Once you start taking Bedaquiline/Snaery, can you stop taking it at will?

Bedaquiline is an anti-tuberculosis drug that targets multi-drug-resistant Mycobacterium tuberculosis. It is an ATP synthase inhibitor and can effectively kill drug-resistant strains by inhibiting the energy metabolism and cell proliferation signals of Mycobacterium tuberculosis. It is widely used in combination treatment regimens for patients with multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB). It is an important breakthrough drug in the treatment of drug-resistant tuberculosis in recent years. Due to its unique mechanism of action and relatively long course of treatment, bedaquiline imposes high requirements on patient compliance and drug management during use.

Once you start taking bedaquiline, you should not stop taking it at will. Indiscriminate interruption of medication can lead to fluctuations in drug blood concentrations, allowing Mycobacterium tuberculosis to survive in the body and may quickly adapt to the drug, leading to drug resistance. This not only reduces the success rate of treatment, but may also lead to recurrence or even worsening of the condition, making second-line drug treatment more difficult. Clinical practice shows that bedaquiline must be used in a complete combination regimen, usually with a treatment course of 24 weeks or longer, and must be used in combination with rifampicin, pyrazinamide, aminoglycosides or other second-line drugs to enhance the bactericidal effect and reduce the risk of resistance.

Throughout the entire treatment process, regular medication and combined medication are key. The use of bedaquiline requires patients to strictly follow the doctor's instructions, take the medicine on time and undergo regular review, including electrocardiogram monitoring, liver function tests and routine blood tests. Since bedaquiline may prolong the QT interval and pose potential cardiac risks to some patients, cardiovascular health status should be assessed before and during treatment, and dose adjustments or other protective measures should be taken if necessary. At the same time, patients with abnormal liver function need to be cautious when using bedaquiline, and if necessary, the starting dose can be reduced under the guidance of a doctor.

Reference materials:https://en.wikipedia.org/wiki/Bedaquiline